Vanda Pharma jumps as US FDA approves new antipsychotic pill

Vanda Pharmaceuticals

23/02/2026 11:31

** Shares of Vanda Pharmaceuticals VNDA.O rise 37% to $7.91 premarket

** On late Friday, the U.S. FDA approved VNDA's drug for the treatment of two serious mental health conditions

** The drug, Bysanti, is an antipsychotic pill aimed at treating schizophrenia and acute bipolar I disorder

** Market exclusivity for Bysanti expected to extend to 2044, "providing a robust foundation for long-term innovation and patient benefit," said H.C. Wainwright analyst

** Vanda's extremely modest enterprise value does not reflect the commercial potential of the company's approved product portfolio, let alone its extensive pipeline - H.C. Wainwright

** In 2025, VNDA rose 84.1%

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))